0

Large-scale Synthesis of GMP Grade alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) Propenamide (LFM-A13), a New Anti-Cancer Drug Candidate

Darin DuMez, Taracad K Venkatachalam, Fatih M Uckun

Arzneimittelforschung. 2007;57(3):155-63.

PMID: 17469650

Abstract:

The leflunomide (CAS 75706-12-6) metabolite (LFM) analog alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl)-propenamide (LFM-A13, DDE-28, CAS 244240-24-2), is a rationally designed inhibitor of the anti-apoptotic enzyme Bruton's tyrosine kinase (BTK). LFM-A13 is being developed as a novel dual-function anticancer drug with apoptosis-promoting and anti-thrombotic properties. LFM-A13 was prepared under current Good Manufacturing Practice (cGMP) conditions on the scale of kilograms.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP62004357 LFM-A13 - CAS 62004-35-7 LFM-A13 - CAS 62004-35-7 62004-35-7 Price
qrcode